Earnings Call Insights: Qiagen N.V. (NYSE:QGEN) Q4 2024 Thierry Bernard, CEO, highlighted that Qiagen surpassed its Q4 2024 ...
It's no wonder 3,000+ shoppers are obsessed. Tamim is a senior beauty writer at InStyle, with nearly a decade of experience writing about beauty, fashion, wellness, and music. She specializes in gift ...
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the ...
If you purchase an independently reviewed product or service through a link on our website, SheKnows may receive an affiliate commission. For anyone with fine hair, the wait for luscious, fuller locks ...
WASHINGTON, D.C. — Every day, millions of Americans make health care decisions without enough information to fully understand the trade-offs between approaches to care and make informed choices for ...
CERo Therapeutics (CERO) dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in acute myeloid leukemia. Per protocol, three patients are planned at ...
Sales in the Critical Care portfolio declined by 1% (CER), affected by a reversal of sales discounts in the same period last year. Operating profit improved significantly, with adjusted EBITDA ...
15d
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback